Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Completed 46Terminated 11Withdrawn 2Not yet recruiting 2Active not recruiting 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Multiple Myeloma 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Triple Negative Breast Neoplasms 1Recurrence 1Neoplasms, Plasma Cell 1Lymphoma, Mantle-Cell 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

Rituximab 3Cyclophosphamide 3obinutuzumab 2fludarabine 2daratumumab 2Specimen Handling 2Prednisone 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Dexamethasone 2Bortezomib 2Biopsy 2Bendamustine Hydrochloride 2zanubrutinib 1venetoclax 1tafasitamab 1selinexor 1prednylidene 1polatuzumab vedotin 1pegaspargase 1orelabrutinib 1nelarabine 1merphos 1glofitamab 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1calaspargase pegol 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma × Bortezomib × Clear all
NCT07513129 2026-04-21

Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
18 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡